Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)

June 13, 2024 11:57 AM EDT Send to a Friend
Jefferies analyst Glen Santangelo reiterated a Buy rating and $36.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX).The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login